Cumberland Pharmaceuticals Inc (NASDAQ: CPIX) is a specialty pharmaceutical company that acquires, develops, and commercializes prescription hospital and acute care products. Revenue comes from selling branded prescription drugs directly into hospital systems and acute care settings, with participation in government pricing programs including Medicaid Drug Rebate and the 340B program. The company owns rights to seven FDA-approved products in the United States as of the FY2025 10-K filed March 9, 2026, including Caldolor (ibuprofen injection) for pain management, Acetadote (acetylcysteine injection), Kristalose (lactulose), Vaprisol (conivaptan injection), and Vibativ (telavancin) for bacterial infections. Cumberland also maintains a clinical pipeline anchored by ifetroban, a first-in-class compound being studied for Duchenne muscular dystrophy-associated cardiomyopathy, idiopathic pulmonary fibrosis, and systemic sclerosis. The company is expanding Vibativ internationally, having received regulatory approval in China and launched in Saudi Arabia, and received regulatory approval for its ibuprofen product in Mexico as of FY2025.

Revenue model

Transactional product sales of branded prescription pharmaceuticals to hospitals and acute care facilities, supported by national group purchasing agreements with organizations including Premier Inc. and Vizient. Revenue is reduced by chargebacks, discounts, rebates, coupons, and product returns. The company also generates income through co-commercialization arrangements and is building international partnership revenue.

Products and services

Caldolor (ibuprofen injection, non-opioid pain management), Acetadote (acetylcysteine injection), Kristalose (lactulose, oral laxative), Vaprisol (conivaptan injection), Vibativ (telavancin, antibiotic for bacterial infections), and additional FDA-approved products. Clinical pipeline includes ifetroban for DMD-associated cardiomyopathy, idiopathic pulmonary fibrosis, and systemic sclerosis.

Customers and end markets

Hospital systems and acute care facilities in the United States. Distributor access through national group purchasing organizations including Premier Inc. and Vizient. International markets including China, Saudi Arabia, and Mexico as of FY2025.

Value-chain role

Downstream specialty pharma commercialization company. Relies on third-party contract manufacturers for all product supply. Acetadote and Vaprisol are each sourced from a single manufacturer. Caldolor is sourced from multiple manufacturers. Kristalose active pharmaceutical ingredient is manufactured at a single facility with one packager in place since 2022.

Geographic exposure

Primary market is the United States. International expansion underway as of FY2025, with Vibativ approved in China and launched in Saudi Arabia, and ibuprofen product approved in Mexico.

Source: SEC 10-K, filed 2026-03-09

Industry: Pharmaceutical Preparations Peers: Item 9 Labs Corp. ALIMERA SCIENCES INC Cognition Therapeutics Inc Hepion Pharmaceuticals Inc Endexx Corp Johnson & Johnson Lipocine Inc NVN Liquidation, Inc. Zynerba Pharmaceuticals, Inc.